These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 37372117)

  • 1. Sialylation: A Cloak for Tumors to Trick the Immune System in the Microenvironment.
    Zhou X; Chi K; Zhang C; Liu Q; Yang G
    Biology (Basel); 2023 Jun; 12(6):. PubMed ID: 37372117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
    Egan H; Treacy O; Lynch K; Leonard NA; O'Malley G; Reidy E; O'Neill A; Corry SM; De Veirman K; Vanderkerken K; Egan LJ; Ritter T; Hogan AM; Redmond K; Peng L; Che J; Gatlin W; Jayaraman P; Sheehan M; Canney A; Hynes SO; Kerr EM; Dunne PD; O'Dwyer ME; Ryan AE
    Cell Rep; 2023 May; 42(5):112475. PubMed ID: 37167967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
    Boelaars K; van Kooyk Y
    Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
    van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
    Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialylation acts as a checkpoint for innate immune responses in the central nervous system.
    Klaus C; Liao H; Allendorf DH; Brown GC; Neumann H
    Glia; 2021 Jul; 69(7):1619-1636. PubMed ID: 33340149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting sialylation to treat central nervous system diseases.
    Lünemann JD; von Gunten S; Neumann H
    Trends Pharmacol Sci; 2021 Dec; 42(12):998-1008. PubMed ID: 34607695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.
    Wielgat P; Czarnomysy R; Trofimiuk E; Car H
    Immunol Res; 2019 Oct; 67(4-5):348-357. PubMed ID: 31741237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant Sialylation in Cancer: Therapeutic Opportunities.
    Munkley J
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialic acids as cellular markers of immunomodulatory action of dexamethasone on glioma cells of different immunogenicity.
    Wielgat P; Trofimiuk E; Czarnomysy R; Braszko JJ; Car H
    Mol Cell Biochem; 2019 May; 455(1-2):147-157. PubMed ID: 30443853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity.
    Huang J; Huang J; Zhang G
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.
    Wang Z; Geng Z; Shao W; Liu E; Zhang J; Tang J; Wang P; Sun X; Xiao L; Xu W; Zhang Y; Cui H; Zhang L; Yang X; Chang X; Qiu X
    Cell Mol Immunol; 2020 Nov; 17(11):1148-1162. PubMed ID: 31754235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new histobiochemical method to analyze sialylation on cell-surface glycoproteins of head and neck squamous-cell carcinomas.
    Bergler W; Riedel F; Schwartz-Albiez R; Gross HJ; Hörmann K
    Eur Arch Otorhinolaryngol; 1997; 254(9-10):437-41. PubMed ID: 9438113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection.
    Huang R; Zheng J; Shao Y; Zhu L; Yang T
    Prog Biophys Mol Biol; 2023 Jan; 177():34-41. PubMed ID: 36265694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of sialylation in gynecologic cancers.
    Yang ST; Liu CH; Chao WT; Liu HH; Lee WL; Wang PH
    Taiwan J Obstet Gynecol; 2023 Sep; 62(5):651-654. PubMed ID: 37678990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Developed NK-92MI Cell Line with Siglec-7
    Huang CH; Liao YJ; Fan TH; Chiou TJ; Lin YH; Twu YC
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29617289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intriguing roles of Siglec family members in the tumor microenvironment.
    Jiang KY; Qi LL; Kang FB; Wang L
    Biomark Res; 2022 Apr; 10(1):22. PubMed ID: 35418152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
    Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment.
    Natoni A; Bohara R; Pandit A; O'Dwyer M
    Front Bioeng Biotechnol; 2019; 7():252. PubMed ID: 31637237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.